Artivion (NYSE:AORT) SVP Jean Holloway Sells 2,183 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 2,183 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $38.02, for a total transaction of $82,997.66. Following the completion of the transaction, the senior vice president directly owned 170,105 shares of the company’s stock, valued at approximately $6,467,392.10. This trade represents a 1.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Stock Performance

NYSE AORT opened at $38.56 on Wednesday. The business has a 50 day moving average price of $41.59 and a 200 day moving average price of $42.95. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The company has a market capitalization of $1.85 billion, a P/E ratio of 192.81 and a beta of 1.60. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. The business’s quarterly revenue was up 19.2% on a year-over-year basis. Sell-side analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

AORT has been the subject of a number of recent research reports. Canaccord Genuity Group dropped their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Citizens Jmp boosted their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Finally, Oppenheimer restated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently bought and sold shares of the stock. Invesco Ltd. boosted its holdings in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the last quarter. XTX Topco Ltd acquired a new stake in Artivion during the fourth quarter worth about $746,000. Susquehanna Portfolio Strategies LLC lifted its stake in shares of Artivion by 21.5% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock valued at $1,849,000 after purchasing an additional 7,186 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Artivion in the 4th quarter valued at about $248,000. Finally, Millennium Management LLC grew its holdings in shares of Artivion by 1.0% during the 4th quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after purchasing an additional 893 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts maintain a constructive view — the consensus rating reported is “Moderate Buy,” and several firms have reiterated buy/outperform ratings and mid‑to‑high price targets, which can support demand for AORT shares. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference (fireside chat), giving the company a chance to update guidance, product progress or commercialization milestones — an event that often attracts buy‑side attention. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Institutional investors have been adding to positions (Invesco, Summit Partners, Goldman Sachs, Two Sigma among those increasing exposure), which can provide steady bid support and signal confidence from larger, professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates (Feb. 12), showing top‑line growth; this underpins the bull case but may already be priced in given prior analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold shares on March 2 (CEO James Mackin sold ~14.9k shares; EVP Lance Berry and several SVPs also sold), a cluster of sales that markets often interpret as a negative signal even though insiders retain large holdings. See the SEC Form 4 for details. SEC Form 4 – Mackin

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.